Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Chimeric interleukin-6 soluble receptor/ligand proteins

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons

Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

METHOD OF IDENTIFYING AGENTS THAT AFFECT MATURATION, SURVIVAL AND MYELINATION

The present invention discloses a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells. 130.-. (canceled)31. A method of making enriched oligodendrocyte precursor cells (OPCs) , comprising:(a) culturing human embryonic stem cells (hES) in a medium comprising retinoic acid and Epidermal Growth Factor (EGF), thereby generating neurospheres;(b) contacting the neurospheres with an adherent substrate comprising an extracellular matrix;(c) following step (b), dissociating the neurospheres;(d) culturing the dissociated neurospheres in a medium comprising EGF and basic Fibroblast Growth Factor (bFGF);(e) following step (d), culturing the dissociated neurospheres in a medium lacking growth factors, thereby generating ex vivo differentiated neural cells;(f) selecting the ex vivo differentiated neural cells to be O4-positive or CD140-positive;(g) expanding, freezing, and thawing the selected neural cells in a medium comprising EGF and bFGF;(h) after thawing, culturing the selected neural cells for at least one day in a medium lacking growth factors; thereby making the enriched OPCs.32. The method of claim 31 , wherein the OPCs further express Hes5.33. The method of claim 31 , wherein the hES in step (a) are aggregated.34. The method of claim 31 , wherein the medium of step (a) further comprises noggin.35. The method of claim 31 , wherein the medium of step (e) comprises noggin.36. The method of claim 31 , wherein the selecting of step (f) is performed by magnetic sorting (MACS) or fluorescence activated cell sorting (FACS).37. A method of quantifying an effect of an agent on myelination of OPCs or on maturation or survival of oligodendrocytes claim 31 , or a combination thereof claim 31 , comprising:{'claim-ref': {'@idref': 'CLM-00031', 'claim 31'}, '(a) making enriched OPCs according to ;'}(b) following step (a), contacting the enriched OPCs with the agent; and,( ...

Enhancement of oligodendrocyte differrentiation

The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.

Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

IL6RIL6 chimera for the treatment of neurodegenerative diseases

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

Synthetic peptides that inhibit IL-6 activity

METHODS OF INDUCING MYELINATION AND MATURATION OF OLIGODENDROCYTES

The present invention disclosed methods of inducing maturation of oligodendrocyte cells. A method of inducing myelination in a patient suffering from demyelination is also disclosed 1. A method of inducing myelination in a patient suffering from demyelination , comprising: administering an effective amount of an inhibitor of a bone morphogenetic protein (BMP) type I receptor to a patient in need thereof.2. The method of claim 1 , wherein the inhibitor is selected from the group consisting of: LDN-193189 claim 1 , K02288 claim 1 , a derivative thereof claim 1 , and a combination thereof.3. The method of claim 1 , wherein the type I BMP receptor is selected from the group consisting of: ALK1 claim 1 , ALK2 claim 1 , ALK3 claim 1 , ALK4 claim 1 , ALK5 claim 1 , ALK6 claim 1 , and ALK7.4. The method of claim 1 , wherein the demyelination is from a disease selected from the group consisting of: multiple sclerosis claim 1 , cerebrovascular accident claim 1 , inflammation claim 1 , and an autoimmune disease claim 1 , or from an injury selected from the group consisting of spinal cord injury and traumatic brain injury.5. A method of inducing commitment or maturation of oligodendrocyte cells claim 1 , the oligodendrocyte cells having been ex-vivo differentiated from glial progenitor cells derived from pluripotent stem cells (PSC) claim 1 , the method comprising: contacting the glial progenitor cells with an inhibitor of a bone morphogenetic protein pathway selected from the group consisting of: LDN-193189 claim 1 , K02288 claim 1 , a derivative thereof claim 1 , and a combination thereof.6. (canceled)7. A method of treating a medical condition of the CNS claim 5 , the method comprising administering to a subject in need thereof a therapeutically effective amount of a committed or mature oligodendrocyte cell generated according to the method of .8. (canceled)9. A pharmaceutical composition comprising a committed mature oligodendrocyte cells of generated according to the ...

Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Nucleic acids encoding chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

INSULIN PRODUCING CELLS DERIVED FROM PLURIPOTENT STEM CELLS

A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

IL6R/IL6 Chimera for Therapy of Chemotherapy-Induced Peripheral Neuropathy

The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.

Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons

Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons

Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. 1. A method of generating neural and glial cells , the method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells , said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.2. A method of generating glial cells , the method comprising:(a) growing human stem cells in the presence of retinoic acid, under conditions which allow formation of neurospheres; and(b) contacting said neurospheres with an agent capable of down-regulating Bone Morphogenic Protein activity thereby generating the glial cells.3. A method of generating oligodendrocytes , the method comprising:(a) growing human stem cells in the presence of retinoic acid under conditions which allow the formation of neurospheres; and(b) contacting said neurospheres with an agent capable of down-regulating Bone Morphogenic Protein activity thereby generating the oligodendrocytes.4. A method of generating neurons , the method comprising:(a) growing human stem cells in the presence of retinoic acid under conditions which allow the formation of neurospheres; and(b) contacting said neurospheres with an agent capable of down-regulating Bone Morphogenic Protein activity under conditions which allow neuronal cells generation, said conditions comprising Sonic Hedgehog (Shh), thereby generating the neurons.5. An isolated oligodendrocyte cell generated according to the method of , or .6. An isolated astrocyte cell generated according to the method of or .7. An isolated neuronal cell generated according to the method of or .8. An ...

METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. 1. A method of generating neural and glial cells , the method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells , said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenetic Protein activity.258.-. (canceled) The present invention relates to methods of generating glia cells such as oligodendrocyte like cells and the use of same for the treatment of medical conditions of the CNS.Myelin, the fatty substance which encloses certain axons and nerve fibers, provides essential insulation, and enables the conductivity of nerve cells which transmit electrical messages to and from the brain.Aberration in myelination can lead to several pathologies in the central nervous system. These include for example, autoimmune diseases (e.g Multiple Sclerosis), congenital leukodystrophies (e.g Pelizaeus-Merzbacher, vanishing white matter, adrenoleukodystrophy), infectious diseases (e.g. progressive multifocal leukoencephalopathy, postinflammatory demyelinated lesions), neurodegenerative diseases (e.g. multisystem degeneration), vascular diseases (vascular leukoencephalopathies, subcortical infarcts), congenital genetic defects (e.g. amyotrophic lateral sclerosis [ALS], Alzheimer disease, Parkinson disease) and brain and spinal cord trauma or injuries which are demyelinative and possibly neoplasms (e.g. oligodendrio-glioma).Treatment of these pathologies may be effected by cell replacement therapies which eventually may allow achieving regional or even global repair of myelin as indicated by experiments in MBP- ...

Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy

The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.

Chimeric Interleukin-6 Soluble Receptor/Ligand Protein, Analogs Thereof and Uses Thereof

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

Synthetic peptides that inhibit IL-6 activity

Novel peptides derived from the gp80 subunit of the IL-6 receptor system which inhibit the activity of IL-6 are provided.

Methods of generating mature oligodendrocytes

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Use of il6r/il6 chimera in nerve cell regeneration

The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.

DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERIAL SCLEROSIS (ALS)

The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed.

Use of il6r/il6 chimera in nerve cell regeneration

The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.

METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

IL6RIL6 chimera for the treatment of neurodegenerative diseases

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed. 1. A method of screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) the method comprising:(a) contacting a population of astrocytes, the astrocytes having been ex-vivo differentiated from pluripotent stem cells (PSC), with the agent;(b) co-culturing the population of astrocytes of step (a) or a conditioned medium thereof with a population of neurons; and(c) quantifying an effect of said agent to enhance survival or neural function of the population of neurons.2. The method of claim 1 , wherein said population of neurons is hypoxic claim 1 , under oxidative stress claim 1 , under glutamate toxicity or under AMPA/kainate toxicity.3. The method of claim 1 , wherein in step (b) the ratio of the population of astrocytes to neurons is greater than 1:1 claim 1 , 10:1 claim 1 , 100:1 claim 1 , 1000:1 claim 1 , or 10 claim 1 ,000:1.4. The method of claim 1 , wherein said astrocytes express each of GFAP claim 1 , GLAST claim 1 , AQP4 claim 1 , or a combination thereof.5. The method of claim 1 , wherein said astrocytes display secretion of neurotrophic factors selected from the group consisting of BDNF claim 1 , GDNF and VEGF.6. The method of claim 1 , wherein the oxidative stress is selected from the group consisting of reactive oxygen species (ROS) claim 1 , HO claim 1 , and any derivative thereof.7. The method of claim 1 , wherein said quantifying is conducted by counting the number of neurons which are under apoptosis.8. The method of claim 7 , wherein said apoptosis is detected by Caspase-3a labeling claim 7 , Annexin V claim 7 , Tubulin-B3 claim 7 , HB9 or DAPI.9. The method of claim 1 , wherein said agent is a small ...

Insulin producing cells derived from pluripotent stem cells

A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

Method of identifying agents that affect maturation, survival and myelination

The present invention discloses a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.

DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERIAL SCLEROSIS (ALS)

The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed. 1. A method of screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) the method comprising:(a) contacting a population of astrocytes, the astrocytes having been ex-vivo differentiated from pluripotent stem cells (PSC), with the agent;(b) co-culturing the population of astrocytes of step (a) or a conditioned medium thereof with a population of neurons; and(c) quantifying an effect of said agent to enhance survival or neural function of the population of neurons.2. The method of claim 1 , wherein said population of neurons is hypoxic claim 1 , under oxidative stress claim 1 , under glutamate toxicity or under AMPA/kainate toxicity.3. The method of claim 1 , wherein in step (b) the ratio of the population of astrocytes to neurons is greater than 1:1 claim 1 , 10:1 claim 1 , 100:1 claim 1 , 1000:1 claim 1 , or 10 claim 1 ,000:1.4. The method of claim 1 , wherein said astrocytes express each of GFAP claim 1 , GLAST claim 1 , AQP4 claim 1 , or a combination thereof.5. The method of claim 1 , wherein said astrocytes display secretion of neurotrophic factors selected from the group consisting of BDNF claim 1 , GDNF and VEGF.6. The method of claim 1 , wherein the oxidative stress is selected from the group consisting of reactive oxygen species (ROS) claim 1 , HO claim 1 , and any derivative thereof.7. The method of claim 1 , wherein said quantifying is conducted by counting the number of neurons which are under apoptosis.8. The method of claim 7 , wherein said apoptosis is detected by Caspase -3a labeling claim 7 , Annexin V claim 7 , Tubulin-B3 claim 7 , HB9 or DAPI.9. The method of claim 1 , wherein said agent is a ...

CHIMERIC SOLUBLE INTERLEUKIN-6 RECEPTOR / LIGAND PROTEIN, ANALOG AND USES

Synthetic peptides that inhibit il-6 activity

Novel peptides derived from the gp80 subunit of the IL-6 receptor system which inhibit the activity of IL-6 are provided.

The use of il6r/il6 chimera in nerve cell regeneration

The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.

Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons

Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

Enhancement of oligodendrocyte differentiation

The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.

Insulin producing cells derived from pluripotent stem cells

A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

Synthetic peptides that inhibit il-6 activity

Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of Amyotrophic Lateral Sclerosis (ALS)

OF THE DISCLOSURE The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed.

Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons

Insulin producing cells derived from pluripotent stem cells

A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

Cloning of cdnas for interferon-induced genes and their use for monitoring the response to interferon

Human DNA encoding enzymes having (2'-5') oligo A syn-thetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared which may be used to raise antibod-ies which recognize and immunoprecipitate (2'-5') oligo A synthetase. Methods of monitoring interferon activ-ity in a subject are presented.

Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)

The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed.

Novel IFN receptor -1 binding proteins, DNA encoding them and methods for modulating cellular response to interferons

Chimeric sIL-6R / IL-6 protein, DNA, vector, cell, method of preparation as well as various uses of said protein

The use of il6r/il6 chimera in nerve cell regeneration

The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.

IFN receptor 1 binding proteins, DNA encoding them, and methods for modulating cellular response to interferons

Method of identifying agents that affect maturation, survival and myelination

The present invention discloses a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.

Method of identifying agents that affect maturation, survival and myelination

Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης

Παρέχονται χιμαιρικές πρωτεΐνες κατασκευασμένες από την σύντηξη της φυσικά απαντώμενης μορφής του διαλυτού υποδοχέα IL-6 και της IL-6 οι οποίες είναι χρήσιμες στην θεραπευτική αγωγή καρκίνου και ηπατικών ανωμαλιών, στην ενίσχυση μεταμόσχευσης μυελού οστών, και σε θεραπευτική αγωγή άλλων σχετιζόμενων με IL-6 καταστάσεων.

Chimäres lösliches interleukin-6 rezeptor/ligand protein, analoge und verwendungen

Synthetische peptide mit il-6 aktivitäthemmung

Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone

Uporaba himer il6ril6 za zdravljenje nevrodegenerativnih bolezni

IL6RIL6 kim¶re for behandlingen av nevrodegenerative sykdommer

Interferon-induced (2'-5') oligo A synthetase gene, mRNA, cDNA and enzymes having (2'-5') oligo A synthetase activity

Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof

Il6ril6 chimera for the treatment of neurodegenerative diseases

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

Il6ril6 chimera for the treatment of neurodegenerative diseases

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

Quimeras il6ril6 destinadas para el tratamiento de las enfermedades neurodegenerativas.

Uso de la quimera IL6RIL6 para la fabricación de un medicamento para el tratamiento y/o la prevención de enfermedades y trastornos neurológicos seleccionados entre el grupo de la degeneración traumática de los nervios, enfermedades desmielinizantes del SNC o del SNP y/o enfermedades neurodegenerativas.

Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen

Il6ril6 chimera for the treatment of neurodegenerative diseases

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

Interferon-induced (2'-5') oligo A synthetase gene, mRNA, cDNA and enzymes having (2'-5') oligo A synthetase activity

Method of identifying agents that affect maturation , survival and myelination

Methods of inducing myelination and maturation of oligodendrocytes

The present invention disclosed methods of inducing maturation of oligodendrocyte cells. A method of inducing myelination in a patient suffering from demyelination is also disclosed

Methods of inducing myelination and maturation of oligodendrocytes

Interferon-induced(2'-5')oligo a synthetase gene,mrna,cdna and enzymes having(2'-5')oligo a synthetase activity